|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 117.66 USD | +0.83% |
|
+0.49% | +19.30% |
| 07-23 | JPMorgan Adjusts Price Target on Incyte to $110 From $105, Maintains Neutral Rating | MT |
| 07-22 | Morgan Stanley Adjusts Price Target on Incyte to $104 From $103, Maintains Equalweight Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Biopharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 23.31B | |||||
| 66.32B | |||||
| 52.6B | |||||
| 43.27B | |||||
| 38.64B | - | ||||
| 29.62B |
- Stock Market
- Stocks
- INCY Stock
- Charts Incyte Corporation
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
